Boehringer Ingelheim

Featured Drug Company Program


Boehringer Ingelheim Solutions Plus

877-814-3915
www.bisolutionsplus.com

Boehringer Ingelheim (BI)’s Solutions Plus offers a variety of support programs to patients prescribed Gilotrif (afatinib) who require financial assistance (Table).

Table Boehringer Ingelheim Oncology Drugs
Drug Indications Patient support programs Contact information
Gilotrif
(afatinib)
Metastatic NSCLC with EGFR mutation; metastatic squamous NSCLC progressing after platinum-based chemotherapy Boehringer Ingelheim Solutions Plus www.gilotrif.com/patients_and_caregivers/support_program/support_program.html
Boehringer Ingelheim Co-pay Assistance Program www.gilotrifhcp.com/solutions-plus/access-reimbursement#financial-support-services-and-tools
EGFR indicates epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.

Eligible patients may have access to free Gilotrif, coverage and reimbursement support, and copay assistance through the Co-pay Assistance Program and the BI Cares Foundation.

The assistance programs differ in structure and eligibility for government-insured, commercially insured, and uninsured patients.

For commercially insured patients, BI Co-pay Assistance Program provides help so patients pay no more than a $25 copay per month for Gilotrif.

For government-insured patients, BI Solutions Plus connects patients with alternative independent funding support programs to help offset the cost of copays, coinsurance, or other treatment-related expenses. Patients may be eligible for BI Cares Foundation support if alternative funding is denied.

For uninsured or underinsured patients with Medicare, the BI Cares Foundation can provide free medication if financial assistance from other foundations is denied.

Eligibility

BI Cares Foundation Patient Assistance Program

The BI Cares Foundation Patient Assistance Program offers Gilotrif free of charge to eligible patients in the United States who meet income and other eligibility criteria, including:

  • Patients must be a US resident and aged ≥18 years
  • Patients cannot be eligible for prescription drug assistance through Medicare, Medicaid, Medicare Part D, or private insurance. Patients under Medicare Part D who cannot afford the Gilotrif costs may be eligible to enroll, as long as they meet other eligibility criteria and do not have any other prescription drug coverage.

Application & Enrollment

Solutions Plus

Completed enrollment form must be faxed to 866-240-4556. A prescription for Gilotrif and a signed patient authorization form must also be submitted for processing. For more information on the enrollment process, call Solutions Plus at 877-814-3915. Solutions Plus contacts the patient to confirm enrollment and insurance benefits and to determine financial support needs.

BI Cares Foundation Patient Assistance Program

Applications must be faxed to 866-851-2827 from a prescriber’s facility. An original valid prescription signed by a physician must be submitted for processing with the application form, documentation of the patient’s income, and any other applicable documents. For more information on this program call 800-556-8317.

Receiving Gilotrif

Solutions Plus

Gilotrif is distributed via BI’s specialty pharmacy partner, Accredo. Gilotrif is also available through select on-site pharmacies, such as select large group practices, National Cancer Institute–designated cancer centers, select hospitals with outpatient clinics, and integrated delivery networks. To speak with a Gilotrif-trained dedicated pharmacist, call Accredo at 844-569-2837.

BI Cares Foundation Patient Assistance Program

Patients accepted into the BI Cares Foundation Patient Assistance Program will have Gilotrif delivered directly to their home; medications are shipped in 90-day supplies.

Other Services

BI Solutions Plus offers other access and reimbursement solutions, including:

  • Assistance with benefit verification, prior authorization, denials, and claims appeals
  • Gilotrif Bridge provides a 15-day supply of Gilotrif to patients (with commercial or Medicare Part D) who experience a payer approval delay of >5 days, allowing patients to start therapy and avoid a prolonged delay
  • The Gilotrif Pledge refunds the patient and the payer for the first month of therapy if eligible patients discontinue Gilotrif before their first refill
  • The Gilotrif Dose Exchange facilitates the transition to a new dose, and eliminates additional copays and payer payments for the drug within 1 month for eligible patients.
The exchange is offered for up to 2 dose adjustments for patients serviced through the Gilotrif Dispensing Network and have ≥9 tablets to exchange.

Gilotrif Dose Exchange forms may be obtained from the Gilotrif Oncology Sales Consultant.